153 related articles for article (PubMed ID: 11564708)
21. Cell scattering of SK-N-MC neuroepithelioma cells in response to Ret and FGF receptor tyrosine kinase activation is correlated with sustained ERK2 activation.
van Puijenbroek AA; van Weering DH; van den Brink CE; Bos JL; van der Saag PT; de Laat SW; den Hertog J
Oncogene; 1997 Mar; 14(10):1147-57. PubMed ID: 9121763
[TBL] [Abstract][Full Text] [Related]
22. Ret receptor tyrosine kinase activates extracellular signal-regulated kinase 2 in SK-N-MC cells.
van Weering DH; Medema JP; van Puijenbroek A; Burgering BM; Baas PD; Bos JL
Oncogene; 1995 Dec; 11(11):2207-14. PubMed ID: 8570170
[TBL] [Abstract][Full Text] [Related]
23. The oncogenic versions of the Ret and Trk tyrosine kinases bind Shc and Grb2 adaptor proteins.
Borrello MG; Pelicci G; Arighi E; De Filippis L; Greco A; Bongarzone I; Rizzetti M; Pelicci PG; Pierotti MA
Oncogene; 1994 Jun; 9(6):1661-8. PubMed ID: 8183561
[TBL] [Abstract][Full Text] [Related]
24. Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease.
Pelet A; Geneste O; Edery P; Pasini A; Chappuis S; Atti T; Munnich A; Lenoir G; Lyonnet S; Billaud M
J Clin Invest; 1998 Mar; 101(6):1415-23. PubMed ID: 9502784
[TBL] [Abstract][Full Text] [Related]
25. Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes.
Castellone MD; Cirafici AM; De Vita G; De Falco V; Malorni L; Tallini G; Fagin JA; Fusco A; Melillo RM; Santoro M
Oncogene; 2003 Jan; 22(2):246-55. PubMed ID: 12527893
[TBL] [Abstract][Full Text] [Related]
26. Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).
Carlomagno F; Vitagliano D; Guida T; Basolo F; Castellone MD; Melillo RM; Fusco A; Santoro M
J Clin Endocrinol Metab; 2003 Apr; 88(4):1897-902. PubMed ID: 12679489
[TBL] [Abstract][Full Text] [Related]
27. Direct phosphorylation of proliferative and survival pathway proteins by RET.
Panta GR; Du L; Nwariaku FE; Kim LT
Surgery; 2005 Aug; 138(2):269-74. PubMed ID: 16153436
[TBL] [Abstract][Full Text] [Related]
28. A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations.
Iwashita T; Murakami H; Kurokawa K; Kawai K; Miyauchi A; Futami H; Qiao S; Ichihara M; Takahashi M
Biochem Biophys Res Commun; 2000 Feb; 268(3):804-8. PubMed ID: 10679286
[TBL] [Abstract][Full Text] [Related]
29. The Shp-1 and Shp-2, tyrosine phosphatases, are recruited on cell membrane in two distinct molecular complexes including Ret oncogenes.
Incoronato M; D'Alessio A; Paladino S; Zurzolo C; Carlomagno MS; Cerchia L; de Franciscis V
Cell Signal; 2004 Jul; 16(7):847-56. PubMed ID: 15115663
[TBL] [Abstract][Full Text] [Related]
30. The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins.
Iervolino A; Iuliano R; Trapasso F; Viglietto G; Melillo RM; Carlomagno F; Santoro M; Fusco A
Cancer Res; 2006 Jun; 66(12):6280-7. PubMed ID: 16778204
[TBL] [Abstract][Full Text] [Related]
31. Ret-mediated mitogenesis requires Src kinase activity.
Melillo RM; Barone MV; Lupoli G; Cirafici AM; Carlomagno F; Visconti R; Matoskova B; Di Fiore PP; Vecchio G; Fusco A; Santoro M
Cancer Res; 1999 Mar; 59(5):1120-6. PubMed ID: 10070972
[TBL] [Abstract][Full Text] [Related]
32. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation.
Iwashita T; Asai N; Murakami H; Matsuyama M; Takahashi M
Oncogene; 1996 Feb; 12(3):481-7. PubMed ID: 8637703
[TBL] [Abstract][Full Text] [Related]
33. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma.
Iwashita T; Kato M; Murakami H; Asai N; Ishiguro Y; Ito S; Iwata Y; Kawai K; Asai M; Kurokawa K; Kajita H; Takahashi M
Oncogene; 1999 Jul; 18(26):3919-22. PubMed ID: 10445857
[TBL] [Abstract][Full Text] [Related]
34. Ultraviolet light induces redox reaction-mediated dimerization and superactivation of oncogenic Ret tyrosine kinases.
Kato M; Iwashita T; Takeda K; Akhand AA; Liu W; Yoshihara M; Asai N; Suzuki H; Takahashi M; Nakashima I
Mol Biol Cell; 2000 Jan; 11(1):93-101. PubMed ID: 10637293
[TBL] [Abstract][Full Text] [Related]
35. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.
Plaza Menacho I; Koster R; van der Sloot AM; Quax WJ; Osinga J; van der Sluis T; Hollema H; Burzynski GM; Gimm O; Buys CH; Eggen BJ; Hofstra RM
Cancer Res; 2005 Mar; 65(5):1729-37. PubMed ID: 15753368
[TBL] [Abstract][Full Text] [Related]
36. A novel type of mutation in the cysteine rich domain of the RET receptor causes ligand independent activation.
Arlt DH; Baur B; Wagner B; Höppner W
Oncogene; 2000 Jul; 19(30):3445-8. PubMed ID: 10918602
[TBL] [Abstract][Full Text] [Related]
37. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.
Michiels FM; Chappuis S; Caillou B; Pasini A; Talbot M; Monier R; Lenoir GM; Feunteun J; Billaud M
Proc Natl Acad Sci U S A; 1997 Apr; 94(7):3330-5. PubMed ID: 9096393
[TBL] [Abstract][Full Text] [Related]
38. Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.
Chappuis-Flament S; Pasini A; De Vita G; Ségouffin-Cariou C; Fusco A; Attié T; Lenoir GM; Santoro M; Billaud M
Oncogene; 1998 Dec; 17(22):2851-61. PubMed ID: 9879991
[TBL] [Abstract][Full Text] [Related]
39. The tyrosine phosphatase Shp-2 mediates intracellular signaling initiated by Ret mutants.
D'Alessio A; Califano D; Incoronato M; Santelli G; Florio T; Schettini G; Carlomagno MS; Cerchia L; de Franciscis V
Endocrinology; 2003 Oct; 144(10):4298-305. PubMed ID: 12959980
[TBL] [Abstract][Full Text] [Related]
40. Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival.
De Vita G; Melillo RM; Carlomagno F; Visconti R; Castellone MD; Bellacosa A; Billaud M; Fusco A; Tsichlis PN; Santoro M
Cancer Res; 2000 Jul; 60(14):3727-31. PubMed ID: 10919641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
